150 related articles for article (PubMed ID: 31666248)
21. Expanded Access and Right To Try Requests: The Community Oncologist's Experience.
Zettler ME; Jeune-Smith Y; Feinberg BA; Phillips EG; Gajra A
JCO Oncol Pract; 2021 Nov; 17(11):e1719-e1727. PubMed ID: 33886355
[TBL] [Abstract][Full Text] [Related]
22. Patient advocacy. 'Right to Try' laws bypass FDA for last-ditch treatments.
Servick K
Science; 2014 Jun; 344(6190):1329. PubMed ID: 24948714
[No Abstract] [Full Text] [Related]
23. How Often Are Drugs Made Available Under the Food and Drug Administration's Expanded Access Process Approved?
McKee AE; Markon AO; Chan-Tack KM; Lurie P
J Clin Pharmacol; 2017 Oct; 57 Suppl 10():S136-S142. PubMed ID: 28921646
[TBL] [Abstract][Full Text] [Related]
24. Federal Right-to-Try Legislation - Threatening the FDA's Public Health Mission.
Joffe S; Lynch HF
N Engl J Med; 2018 Feb; 378(8):695-697. PubMed ID: 29320302
[No Abstract] [Full Text] [Related]
25. Questions of Safety and Fairness Raised as Right-to-Try Movement Gains Steam.
Jacob JA
JAMA; 2015 Aug; 314(8):758-60. PubMed ID: 26244653
[No Abstract] [Full Text] [Related]
26. Right-to-Try Investigational Therapies for Incurable Disorders.
Simmons Z
Continuum (Minneap Minn); 2017 Oct; 23(5, Peripheral Nerve and Motor Neuron Disorders):1451-1457. PubMed ID: 28968371
[TBL] [Abstract][Full Text] [Related]
27. Charging for investigational drugs under an investigational new drug application. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2009 Aug; 74(155):40871-900. PubMed ID: 19691172
[TBL] [Abstract][Full Text] [Related]
28. Expanding Patient Access to Investigational Drugs: Single Patient Investigational New Drug and the "Right to Try".
Van Norman GA
JACC Basic Transl Sci; 2018 Apr; 3(2):280-293. PubMed ID: 30062214
[TBL] [Abstract][Full Text] [Related]
29. FDA Aims to Broaden Access to New Therapies.
Cancer Discov; 2023 Oct; 13(10):OF3. PubMed ID: 37565721
[TBL] [Abstract][Full Text] [Related]
30. Right to experimental treatment: FDA new drug approval, constitutional rights, and the public's health.
Leonard EW
J Law Med Ethics; 2009; 37(2):269-79. PubMed ID: 19493072
[TBL] [Abstract][Full Text] [Related]
31. Before It's Too Late: Multistakeholder Perspectives on Compassionate Access to Investigational Drugs for Pediatric Patients With Cancer.
Gerasimov E; Donoghue M; Bilenker J; Watt T; Goodman N; Laetsch TW
Am Soc Clin Oncol Educ Book; 2020 May; 40():1-10. PubMed ID: 32412804
[TBL] [Abstract][Full Text] [Related]
32. Compassionate use in research.
Miracle VA
Dimens Crit Care Nurs; 2009; 28(2):85-8. PubMed ID: 19225323
[TBL] [Abstract][Full Text] [Related]
33. Implementation of 21st Century Cures Act Expanded Access Policies Requirements.
Kang S; Chang S; Ross JS; Miller JE
Clin Pharmacol Ther; 2021 Dec; 110(6):1579-1584. PubMed ID: 34431083
[TBL] [Abstract][Full Text] [Related]
34. Perspectives of Academic Oncologists About Offering Expanded Access to Investigational Drugs.
Gould P; Salam T; Kimberly L; Bateman-House A; Fernandez Lynch H
JAMA Netw Open; 2022 Nov; 5(11):e2239766. PubMed ID: 36318206
[TBL] [Abstract][Full Text] [Related]
35. Recommendations to Facilitate Expanded Access to Investigational Therapies for Seriously Ill Patients.
Jerome RN; Edwards TL; Boswell HC; Bernard GR; Harris PA; Pulley JM
Acad Med; 2016 Mar; 91(3):305-9. PubMed ID: 26445080
[TBL] [Abstract][Full Text] [Related]
36. Free to Choose: A Moral Defense of the Right-to-Try Movement.
Brodrick M
J Med Philos; 2020 Jan; 45(1):61-85. PubMed ID: 31922578
[TBL] [Abstract][Full Text] [Related]
37. The strange allure of state "right-to-try" laws.
Zettler PJ; Greely HT
JAMA Intern Med; 2014 Dec; 174(12):1885-6. PubMed ID: 25264589
[No Abstract] [Full Text] [Related]
38. Expanded Access to Investigational Drugs: What Physicians and the Public Need to Know about FDA and Corporate Processes.
Finkelstein PE
AMA J Ethics; 2015 Dec; 17(12):1142-6. PubMed ID: 26698587
[No Abstract] [Full Text] [Related]
39. No way to save a life: allowing terminally ill patients access to drugs that have not completed clinical trials is a dangerous move.
Moss RW
New Sci; 2006 Jun 3-9; 190(2554):21. PubMed ID: 16832956
[No Abstract] [Full Text] [Related]
40. US Food and Drug Administration Efforts to Facilitate the Use of Expanded Access Programs.
Kim T; Lurie P; Pazdur R
J Clin Oncol; 2015 Nov; 33(33):3979-80. PubMed ID: 26282656
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
